Y

et another showdown over the high cost of medicines is taking place in Ireland, where the government and the maker of a cystic fibrosis treatment are locked in a battle that has enraged and worried patients.

The struggle is over Orkambi, a drug sold by Vertex Pharmaeuticals that has a price tag of about $170,000 a year. But Ireland’s National Centre for Pharmacoeconomics determined the medicine would be cost effective only if it were priced at about $32,000 per patient and did not recommend reimbursement. Consequently, Ireland’s Health Service Executive has so far refrained from providing coverage.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.